Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chronotherapeutic dosage forms

a technology of chromotherapy and dosage form, which is applied in the direction of drug composition, immunological disorders, cardiovascular disorders, etc., can solve the problems of disintegration typically having a detrimental effect, osteoarthritis getting worse, and the most likely to suffer a heart attack or stroke, so as to facilitate the immediate promote the release of the drug, and facilitate the effect of drug releas

Inactive Publication Date: 2005-06-02
PENWEST PHARMA CO
View PDF99 Cites 70 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] It is a further object of the present invention to provide an oral pharmaceutical dosage form that provides a delayed release of a drug(s) into the gastrointestinal tract of a patient at a predetermined time after oral ingestion of the dosage form.
[0029] In certain preferred embodiments, the inclusion of the surfactant in the core of the dosage form facilitates the complete release of the drug from the dosage form in less than 4 hours after initial release, preferably in less than 3 hours after initial release, more preferably in less 2 hours after initial release, and most preferably in less than 1 hour after initial release.

Problems solved by technology

When one wakes up, hay fever is at its most tormenting, and in the morning hours, as ones blood pressure rises to meet the day, one is most likely to suffer a heart attack or stroke.
Rheumatoid arthritis improves through the day, but osteoarthritis grows worse.
This disintegration would typically have a detrimental effect upon the sustained release of the active agent.
Such coated pharmaceutical formulations, in addition to slowing the release rate of the active agent contained within the core of the tablet, can also effectuate a delay in the release of the active ingredient for a desired period of time such that the dissolution of the active drug core can be delayed.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0190] A delayed release material to be used in the compression coatings of the invention is prepared having the following formulation listed in Table 1:

TABLE 1ComponentPercentage1. Xanthan Gum32. Locust Bean Gum4.53. Mannitol92.54. Water*q.s. (20-40)

*Removed during processing

The process for the preparation of the delayed release material is as follows:

Process: [0191] 1. The requisite amounts of xanthan gum, locust bean gum, and mannitol are dry blended in a high speed mixer / granulator for 3 minutes. [0192] 2. Water is added to the dry blended mixture, and granulated for another 3 minutes. [0193] 3. The granulation is then dried in a fluid bed dryer to a LOD (loss on drying) of less than about 10% by weight (e.g., 4-7% LOD).

example 2

[0194] A delayed release material to be used in the compression coatings of the invention is prepared having the formulation listed in Table 2:

TABLE 2ComponentPercentage1. Xanthan Gum62. Locust Bean Gum93. Mannitol854. Water*q.s. (20-40)

*Removed during processing

Process:

[0195] The same process for Example 1 is used to prepare the delayed release material of Example 2 to be used in the compression coatings of the invention.

example 3

[0196] A delayed release material to be used in the compression coatings of the invention is prepared having the formulation listed in Table 3:

TABLE 3ComponentPercentage1. Xanthan Gum202. Locust Bean Gum303. Mannitol504. Water*q.s. (20-40)

*Removed during processing

Process:

[0197] The same process for Example 1 is used to prepare the delayed release material of Example 3 to be used in the compression coatings of the invention.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
total weightaaaaaaaaaa
Login to View More

Abstract

A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.

Description

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60 / 504,037, filed on Sep. 19, 2003, the disclosure of which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to a chronotherapeutic dosage form containing a therapeutically effective amount of a drug. The present invention is further related to methods of preparing such formulations, and to methods of treatment utilizing such formulations. BACKGROUND OF THE INVENTION [0003] Coordinating biological rhythms (chronobiology) with medical treatment is called chronotherapy. Chronotherapy takes into consideration a person's biological rhythms in determining the timing—and sometimes the amount—of medication to optimize desired effects of a drug(s) and minimize the undesired effects. The synchronization of medication levels to the biological rhythms of disease activity is playing an increasing role in the management of common cardiovascular cond...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61KA61K9/26A61K31/573
CPCA61K9/5036A61K9/501A61P11/06A61P19/02A61P29/00A61P37/08A61P9/00A61P9/10A61P9/12A61K9/2054
Inventor BAICHWAL, ANAND R.WOODCOCK, PAULLABUDZINSKI, STEVE
Owner PENWEST PHARMA CO
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products